CSIMarket
 
Aim Immunotech Inc   (AIM)
Other Ticker:  
 
 
Price: $0.4200 $0.04 10.818%
Day's High: $0.43 Week Perf: 5 %
Day's Low: $ 0.38 30 Day Perf: -0.02 %
Volume (M): 240 52 Wk High: $ 0.75
Volume (M$): $ 101 52 Wk Avg: $0.50
Open: $0.39 52 Wk Low: $0.38



 Market Capitalization (Millions $) 20
 Shares Outstanding (Millions) 49
 Employees -
 Revenues (TTM) (Millions $) 0
 Net Income (TTM) (Millions $) -21
 Cash Flow (TTM) (Millions $) -15
 Capital Exp. (TTM) (Millions $) 1

Aim Immunotech Inc
Aim Immunotech Inc is a biotechnology company that focuses on the development and commercialization of novel drugs for the treatment of various diseases. The company's main focus is on developing therapies that modulate the immune system to fight diseases such as cancer, viral infections, and immune disorders. Aim Immunotech Inc utilizes its proprietary technology called Ampligen to stimulate the immune response and enhance the effectiveness of immunotherapies. The company's goal is to provide innovative and effective treatment options for patients with unmet medical needs.


   Company Address: 2117 SW Highway 484 Ocala 34473 FL
   Company Phone Number: 448-7797   Stock Exchange / Ticker: NYSEAMER AIM
   AIM is expected to report next financial results on March 30, 2024.


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
• View Complete Report
   



Clinical Study

The Synergistic Impetus: Unleashing Ampligen and Imfinzi for Pancreatic Cancer Treatment

Published Wed, Feb 14 2024 1:55 PM UTC

In a stride towards revolutionizing pancreatic cancer treatment, AIM ImmunoTech has recently administered its first subject in the Netherlands for a Phase 1b/2 study evaluating the combination of Ampligen (rintatolimod) with AstraZeneca's Imfinzi (durvalumab). This groundbreaking endeavor aims to unlock novel therapeutic possibilities to combat the grave challenges posed by ...

Product Service News

Pioneering Phase 1b/2 Study of Ampligen in Concert with Imfinzi for Late-Stage Pancreatic Cancer Launched with First Patient Enrollment

Published Mon, Jan 22 2024 1:55 PM UTC

AIM ImmunoTech, a biotechnology company focused on the research and development of therapeutic treatments for multiple types of cancers, recently announced a milestone in its latest clinical trial. The company has accomplished the first patient enrolment at the Erasmus Medical Center in Rotterdam, Netherlands. This marks the beginning of their Phase 1b/2 clinical study which...

Clinical Study

An Analysis of the Emerging Interventional Techniques for Pancreatic Cancer: A Look into AIM ImmunoTech's Phase 1b/2 Study of Ampligen in Cohesion with AstraZeneca's Imfinzi

Published Wed, Jan 10 2024 1:45 PM UTC

Pancreatic cancer, notorious for its aggressive nature and reduced survivorship index, has remained an area of considerable concern in the domain of clinical medicine. The medical industry has fervently been scouting for innovative and effective therapeutic interventions for this grave medical condition. One of the leading biotechnology firms, AIM ImmunoTech, recently announ...

Product Service News

AIM ImmunoTech's Ampligen Shows Potential in Promising Breast Cancer Study

Published Tue, Nov 14 2023 3:01 PM UTC



AIM ImmunoTech, a leading biopharmaceutical company, has announced the publication of exciting data from a Phase 1 study of Ampligen at the Roswell Park Comprehensive Cancer Center. The study evaluated the use of Ampligen as a component of a Chemokine-Modulating (CKM) regimen in patients with metastatic triple-negative breast cancer. Published in The Journal for Im...

Earnings announcement

AIM ImmunoTech Teams Up with Azenova to Accelerate Breakthrough Cancer Treatment Development

Published Tue, Oct 17 2023 12:45 PM UTC

AIM ImmunoTech, a leading biopharmaceutical company, has announced its collaboration with Azenova, a renowned business development consulting firm. The partnership aims to accelerate the partnering, development, and commercialization efforts for AIM ImmunoTech's pipeline programs, with a specific focus on their most promising asset, Ampligen. This cutting-edge drug holds imm...






 

Aim Immunotech Inc's Segments
 
 
• View Complete Report
  Company Estimates  
  Revenue Outlook
Aim Immunotech Inc does not provide revenue guidance.

Earnings Outlook
Aim Immunotech Inc does not provide earnings estimates.

 
Geographic Revenue Dispersion




Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com